Halozyme Therapeutics Inc (HALO) FinancialsHALOHalozyme Therapeutics Inc

Halozyme Therapeutics, Inc. (HALO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Royalties, accounting for 64.0% of total sales, equivalent to $307.70M. Other significant revenue streams include Sales of bulk rHuPH20 and Sales of proprietary products. Understanding this composition is critical for investors evaluating how HALO navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Halozyme Therapeutics, Inc. maintains a gross margin of 77.40%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 59.80%, while the net margin is 47.80%. These profitability ratios, combined with a Return on Equity (ROE) of 173.67%, provide a clear picture of how effectively HALO converts its operational activities into shareholder value.

In the context of the broader market, HALO competes directly with industry leaders such as NBIX and BBIO. With a market capitalization of $13.26B, it holds a significant position in the sector. When comparing efficiency, HALO's gross margin of 77.40% stands against NBIX's 95.87% and BBIO's 93.83%. Such benchmarking helps identify whether Halozyme Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Halozyme has shown impressive revenue growth, with Q2 2026 revenue at $480,999,000, up from $354,264,000 in Q3 2025. The gross margin is also strong at 77.40% for Q2 2026, indicating effective cost management and profitability.